Empery Asset Management’s NeuroSense Therapeutics Warrant NRSNW Stock Holding History
Bought
Maintained
Sold
Other funds holding NRSNW
Empery Asset Management's NRSNW Position: Q3 2026 in Review
Empery Asset Management reduced its NeuroSense Therapeutics Warrant (NRSNW) stake by 4.9% in Q3 2026, selling an estimated $349 and leaving 95,499 shares worth $4.3K. The position accounts for ﹤0.01% of the portfolio, ranked #32.
Empery Asset Management first reported a position in NRSNW in Q4 2021 and has held it in 8 quarters since. The position peaked at $96K in Q1 2022. 3 funds tracked by Wall St. Rank hold NRSNW as of Q3 2026.
- Empery Asset Management held 95,499 shares of NeuroSense Therapeutics Warrant worth $4.3K as of Q3 2026.
- Empery Asset Management sold 4,903 NeuroSense Therapeutics Warrant shares in Q3 2026, an estimated $349.
- NeuroSense Therapeutics Warrant made up ﹤0.01% of Empery Asset Management's portfolio in Q3 2026, its #32 holding.
- Empery Asset Management first reported a position in NeuroSense Therapeutics Warrant in Q4 2021 and has held it in 8 quarters since.
- Empery Asset Management's NeuroSense Therapeutics Warrant position peaked at $96K in Q1 2022.
- 3 funds tracked by Wall St. Rank held NeuroSense Therapeutics Warrant as of Q3 2026.
Based on Empery Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.